Sökning: L773:1532 6535 OR L773:0009 9236
> (2020-2024) >
Understanding Stati...
-
Dong, JinClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USA
(författare)
Understanding Statin-Roxadustat Drug–Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
John Wiley & Sons,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-515429
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-515429URI
-
https://doi.org/10.1002/cpt.2980DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug–drug and disease (drug-drug-disease interaction (DDDI)). Physiologically-based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin-roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four-way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin-rifampicin DDIs in patients and the statin-roxadustat DDIs in HVs within 1.25- and 2-fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin-roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK-guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co-administered with roxadustat.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Garcia, Luna Prieto,1988-Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca Gothenburg Sweden,Translational Drug Discovery and Development(Swepub:uu)lunga165
(författare)
-
Huang, YingboDepartment of Experimental and Clinical Pharmacology University of Minnesota Minneapolis Minnesota USA
(författare)
-
Tang, WeifengClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USA
(författare)
-
Lundahl, AnnaDrug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca Gothenburg Sweden;Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gothenburg Sweden
(författare)
-
Elebring, MarieDrug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca Gothenburg Sweden
(författare)
-
Ahlström, ChristineDrug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca Gothenburg Sweden
(författare)
-
Vildhede, AnnaDrug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca Gothenburg Sweden
(författare)
-
Sjögren, Erik,1977-Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Translational Drug Discovery and Development(Swepub:uu)ersjo473
(författare)
-
Någård, MatsClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USA
(författare)
-
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USAInstitutionen för farmaceutisk biovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Clinical Pharmacology and Therapeutics: John Wiley & Sons114:4, s. 825-8350009-92361532-6535
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Dong, Jin
-
Garcia, Luna Pri ...
-
Huang, Yingbo
-
Tang, Weifeng
-
Lundahl, Anna
-
Elebring, Marie
-
visa fler...
-
Ahlström, Christ ...
-
Vildhede, Anna
-
Sjögren, Erik, 1 ...
-
Någård, Mats
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmaceutiska ve ...
- Artiklar i publikationen
-
Clinical Pharmac ...
- Av lärosätet
-
Uppsala universitet